RAG-17 extended study for ALS with SOD1 mutation
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial tests a new treatment called RAG-17 for people with ALS who have a specific genetic change (SOD1 mutation). The goal is to see if it can slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have a confirmed SOD1 gene mutation known to cause ALS
- Have a definite or probable diagnosis of ALS (family or sporadic type)
- Not have certain SOD1 mutations (at positions 44-66 or the F21C change)
- Be medically stable with no severe liver, kidney, or heart problems
- Not be pregnant, breastfeeding, or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if tofersen, a drug that targets a protein linked to ALS, can help people who have ALS but do not have mutations in the SOD1 or FUS genes. It aims to slow disease progression in those diagnosed within the last 2 years.
This study aims to match people with ALS to potential treatments based on their genetic profile. It connects you to a network of trials that may be relevant to your specific type of ALS.
This trial tests a new drug, RAG-17, for people with ALS who have a specific SOD1 gene mutation. The goal is to see if it's safe and how it affects the body, which may help slow the disease.
This trial tests an experimental drug called ALN-SOD for people with ALS caused by a specific genetic mutation in the SOD1 gene. The goal is to see if it is safe and can help slow the disease.
This trial tests a new drug called RAG-21 for people with ALS who have a specific change in their FUS gene. The goal is to see if it is safe and if it can slow down the disease.
This trial tests a new treatment aimed at restoring the function of a gene called UNC13A in people with ALS. It involves multiple clinic visits, MRI scans, and spinal taps to see if the treatment is safe and may slow the disease.
Hear when a new ALS (Amyotrophic Lateral Sclerosis) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.